Jasper Hellweg

Blackhawk Network Holdings Inc (NASDAQ: HAWK) announced a going-private transaction where it will be acquired by private equity firms Silver Lake and P2 Capital for $3.5 billion or $45.25 per share. With shares trading up since the Jan. 15 announcement and inching close to Argus' prior price...

Quest Diagnostics Inc (NYSE: DGX) has a number of bullish catalysts on the horizon, enough for one Wall Street analyst to upgrade the stock. The Analyst Argus analyst Jasper Hellweg upgraded Quest from Hold to Buy and set a $116 price target for the stock. The Thesis Quest simply has too strong...

Bioverativ Inc (NASDAQ: BIVV) agreed to be acquired by Sanofi SA (ADR) (NYSE: SNY) in an $11.6-billion all-cash deal, with the offer price valuing each of Bioverativ shares at $105. The offer price represents a 64-percent premium to Bioverativ's closing price prior to the deal announcement...

It was a huge year for bitcoin and other cryptocurrency investors in 2017, and the Bitcoin Investment Trust (OTC: GBTC) has come out of the gates hot in 2018 as well. While cryptocurrency remains one of the most controversial topics on Wall Street, bitcoin bulls see plenty of upside remaining. 3...

Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s business has faced multiple pressures, including industry-wide price erosion, a legal battle for possible collusion in generic drug pricing along with a management transition. At the same time, some analysts see the bullish case for owning the...

Analysts at Argus Research turned bullish on Bioverativ Inc (NASDAQ: BIVV) as the company could establish itself as a profitable biotech within the hemophilia and blood disorders space. The firm's Jasper Hellweg upgraded Bioverativ's stock from Hold to Buy. Bioverativ was spun-off by Biogen...

Analysts at Argus Research turned bearish on Equifax Inc. (NYSE: EFX) as the company's data breach could prove to be the "most serious" data-hack in history. Analyst Jasper Hellweg downgraded Equifax's stock from Buy to Hold with no assigned price target. Equifax's management...

Argus said in a note that it sees bullish growth outlook for Incyte Corporation (NASDAQ: INCY) given its solid late-stage pipeline and key strategic R&D partnerships with companies such as Merck & Co., Inc. (NYSE: MRK), Novartis AG (ADR)(NYSE: NVS), Bristol-Myers Squibb Co (NYSE: BMY)...

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its...